Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the Board). Dr. Berman will serve as a non-voting observer to the Board through Atea’s 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. The Company is adding Dr. Berman to the Board as part of its entry into an agreement (the Agreement) with Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the Radoff-JEC Group). In connection with the Agreement, the Radoff-JEC Group has withdrawn its slate of nominated director candidates and has agreed to vote all of the shares it collectively owns in favor of each of Atea’s Board nominees at the 2025 Annual Meeting.

Latham & Watkins LLP advised Atea in connection with the agreement with the Radoff-JEC Group with a team led by partners Christopher Drewry, Global Co-Chair of the firm’s Shareholder Activism & Takeover Defense Practice, and Jenna Cooper, Global Vice Chair of the firm's Public Company & Board Representation Practice, with associates Adam Tamzoke, Katie Marren, Jack DeMeulenaere, and Claudia Wang.